875573-66-3 Usage
Description
(7a,17b)-7-(9-Bromononyl)-estra-1,3,5(10)-triene-3,17-diol 17-acetate, commonly known as tibolone, is a synthetic steroid hormone derived from progesterone. It possesses a unique combination of estrogenic, progestogenic, and androgenic properties, making it a versatile compound for hormone replacement therapy in menopausal women.
Uses
Used in Menopause Management:
Tibolone is used as a hormone replacement therapy agent for managing menopausal symptoms in women. It helps alleviate symptoms such as hot flashes and vaginal dryness, providing relief and improving the quality of life for menopausal women.
Used in Bone Health:
Tibolone is used as a bone health supplement to prevent bone loss and reduce the risk of fractures in postmenopausal women. Its estrogenic effects help maintain bone density, promoting overall skeletal health.
Used in Mood Regulation:
Tibolone is used as a mood enhancer in menopausal women, as it has been found to have beneficial effects on mood and emotional well-being. Its androgenic properties may contribute to improved mood stability.
Used in Sexual Function Improvement:
Tibolone is used to improve sexual function in menopausal women. Its estrogenic and androgenic properties help address issues related to sexual desire, arousal, and satisfaction, enhancing overall sexual health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 875573-66-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,5,5,7 and 3 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 875573-66:
(8*8)+(7*7)+(6*5)+(5*5)+(4*7)+(3*3)+(2*6)+(1*6)=223
223 % 10 = 3
So 875573-66-3 is a valid CAS Registry Number.
875573-66-3Relevant articles and documents
Impurity control method of fulvestrant
-
, (2020/09/23)
The invention belongs to the field of pharmaceutical chemicals, and relates to a fulvestrant impurity control method, which is characterized in that from the introduction of chiral carbon to the synthesis of a fulvestrant intermediate compound represented by a formula VII-1, multi-step and step-by-step control is performed on 7beta isomer impurities, so that the 7beta isomer content of the VII-1 compound is between 0.1% and 0.3%, and finally the qualified fulvestrant bulk drug with stable quality is prepared. The impurity control method is simple to operate, low in production cost and high intotal yield, and can be applied to large-scale industrial production.
An alternative synthesis of the breast cancer drug fulvestrant (Faslodex): catalyst control over C-C bond formation
Caprioglio, Diego,Fletcher, Stephen P.
, p. 14866 - 14868 (2015/10/06)
Fulvestrant (Faslodex) was synthesized in four steps (35% overall yield) from 6-dehydronandrolone acetate. Catalyst controlled, room temperature, diastereoselective 1,6-addition of the zirconocene derived from commercially available 9-bromonon-1-ene was used in the key C-C bond forming step.